• 2020 IND Enabling Toxicology
• 20th Anniversary
• Analytical Challenges for CMC Development of Cell and Gene Therapy Products – Webinar
• Assays
• Blog
• Button test
• Central Lab Intake Form
• Central Lab Sample Shipment Order Form
• Conferences & Events
• Enroll in a Study
  • Participating in a Clinical Study
  • Refer a Friend
  • About our Clinic
  • FAQS
• Frontage Laboratory Virtual Tours
• Investor Relations
  • Announcements & Circulars
  • Corporate Governance
  • Corporate Information
  • Financial Reports
  • Investor Inquiries
  • Listing Documents
  • Stock Information
• mall test
• MAP TEST 2
• Medicover and TDL Sample Shipment Order Form
• Newsletter Sign Up
• OLD – History of Frontage Timeline – Single Side
• Operating Status
• PAGE ITEM TEMPLATES TO COPY
• Panel Discussion
• password protect test
• PK Stabilzation Workflow
• Plugins
• Resources On Demand
• Sample Page
• Schedule A Meeting!
• Services & Solutions
  • Bioanalytical
  • Product Development & Manufacturing
• Services Subpage
• Stay Connected
• Submission success!
• Synnovation Sample Shipment Order Form Submission
• Thank you for signing up!
• Thank you!
• Thank You!
• The History of Frontage
• Home
• About
  • Company Overview
  • History of Frontage
  • Executive Leadership
  • Locations
  • Environmental, Social, & Governance
  • Awards and Recognition
  • Quality Assurance
  • Careers
  • Frontage Visitor’s Guide
• Browse Studies
• Resources
  • Overview
• News & Insights
• Contact Us
  • Thank You – Contact Us
• Frontage Milan SIR9900 Sample Shipment Order Form
• MKPK STABILIZATION TUBE ORDER FORM
• Privacy Policy
• Site Map
• Terms of Use
• Inscribirse en estudio clínico
  • Participa en un estudio clínico
  • Refiere a un amigo
  • Sobre Nuestra Clínica
  • Preguntas Frecuentes
• Contáctenos
• Thank You – Apply Online

Posts by category

• Category: Article
  • From Paper to Cloud: How Frontage Digital Lab is Redefining Compliance and Efficiency
  • A Complete Overview of DART (Developmental and Reproductive Toxicology) Studies
  • Microsampling and Dried Blood Spot (DBS) Techniques in Bioanalytical Assays 
  • Flow Cytometry in Early Drug Discovery
  • Product Development of Sterile Nanoemulsions
  • CAP Accreditation – Frontage Central Labs and Our Commitment to Quality
  • Gyrolab: Design, Challenges, and Advantages
  • Harnessing the Microbiome Potential 
  • Circulating Tumor DNA: An Alternative to Tissue NGS for NSCLC
  • Analyzing Cell-free DNA (cfDNA) for Biomarker Discovery 
  • Implementing ICH M10: Finally, a Harmonized Bioanalytical Method Validation Guidance
• Category: Ask the Experts
  • Critical Reagents Usage in Bioanalytical Labs: Q+A with Dr. Santosh Shah
  • The Use of Flow Cytometry in Cell and Gene Therapies
• Category: Bioanalytical
• Category: Central Labs
• Category: CMC
• Category: Discovery
• Category: DMPK
• Category: Featured
• Category: Genomics
  • Cell and Gene Therapy Development for Oncology: An Interview with David Willoughby
• Category: Interview
• Category: Safety and Toxicology

News Items

• Frontage Promotes Dr. Xin (James) Huang to Senior Vice President, Corporate QA & IT
• Frontage Promotes Dr. Xiaonan Tang to Senior Vice President, Bioanalytical Services
• Frontage Laboratories Completes Acquisition of Teddy Lab, Strengthening Global Central Laboratory Capabilities
• Frontage Laboratories Expands Early Phase Clinical Capabilities to Support Global Drug Development
• Frontage Europe Has Relocated Its Bioanalytical Laboratory and Further Expands Its Capabilities
• Frontage CDMO Fully Operational GMP Facility is Ready for Your Needs of Clinical Trials and Commercial Production
• Frontage Achieves Three Successful FDA Inspections in 2025 with NAI Classification
• GCCL and Frontage Laboratories Announce Strategic Collaboration to Strengthen Global Clinical Trial Capabilities
• Frontage Strengthens Global GDDS and DMPK Leadership
• Frontage Announces Expansion of Business in Canada with New Leadership
• Qiang Xu, Ph.D. Joins Frontage as the Vice President, Global Genomics Services
• Frontage Achieves ISO/IEC 27001:2022 Certified
• Expansion of Frontage Laboratories Continues with Launch of New State-of-the-Art CRDMO Facility in Exton, PA
• Frontage Announces Co-CEO Promotions
• Frontage Laboratories and Medicover Integrated Clinical Services Announce Strategic Collaboration to Expand Global Genomic Testing Services
• Frontage announces the promotion of Dr. Wentao Zhang as Chief Strategy Officer
• John Choi, MS Joins Frontage as the Vice President of Clinical Services
• EPNextS Group and Frontage Laboratories, Inc. Announce Collaboration in Early Phase Clinical Trials
• Frontage Laboratories, Inc. and Telomir Pharmaceuticals, Inc. present Promising Pre-clinical Data for Telomir’s Lead Development Product
• Frontage welcomes Dr. John C. Bernal as VP Global Animal Welfare & Veterinary Resources
• Frontage Laboratories Acquires Accelera S.r.l.’s Bioanalytical and DMPK Businesses
• Frontage welcomes Dr. Yaodong Huang, PhD as Senior Vice President, ACME
• Frontage announces an initiative to form Global Drug Discovery Services
• Frontage Acquires Nucro-Technics Inc. and Nucro-Technics Holdings, Inc.
• Frontage Receives Multiple 2023 CRO Leadership Awards
• Frontage welcomes Dr. John Kapeghian as the Senior Vice President of Global Safety & Toxicology
• Frontage welcomes Dr. James Huang as VP of Corporate Quality Assurance
• Stewart Jacobson, DVM, DACVP joins Frontage as Vice President, Pathology Services
• Frontage Announces CEO and President Promotions
• Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer’s Drug, Lecanemab
• Stephen Gacheru PhD. joins Frontage as Vice President, Cell and Gene Therapy Operations
• James Houston joins Frontage as Vice President of Information Technology
• Frontage Central Labs is Awarded the Prestigious CAP Accreditation from the College of American Pathologists
• Martin Poirier joins Frontage Laboratories as Executive Director and Head of BRI/Frontage Canada
• Frontage Announces Opening of Custom-Built State-of-the-Art Laboratory Facility in Hayward, CA
• Jeffrey Yablon joins Frontage Laboratories as Senior Vice President
• Frontage Holdings Announces 2022 Interim Results
• Frontage Laboratories Inc. Acquires Frontage Clinical Services Inc.
• Frontage Holdings Announces Annual Results
• Frontage Laboratories Achieves Key Milestone for its Suzhou Toxicology Facility
• Frontage Expands Toxicology Services Through the Acquisition of Experimur
• Frontage Laboratories, Inc is a PanaBIOS Trusted Travel Approved COVID-19 Laboratory Testing Provider.
• Frontage Expands Early Drug Discovery Services through the Acquisition of Heyan Biotech
• Frontage Holdings Announces 2021 Interim Results
• Dr. Raj Yadwad joins Frontage Laboratories as VP Product Development & Manufacturing.
• Frontage Opens a New State-of-the-Art Laboratory Facility in Exton, PA
• Larry Veal joins Frontage Laboratories, Inc. as the Senior Vice President of North America Sales and Marketing
• Frontage Laboratories, Inc. to Acquire Quintara Discovery, Inc.
• Sudendra Rao Ph.D. joins Frontage as Senior Vice President, Human Resources, North America
• Dr. Daniel Schulz-Jander joins Frontage as the Laboratory Head, Frontage Hayward
• John Foster joins Frontage Laboratories, Inc. as Executive Director, Regional Head of Sales, West
• Frontage Announces Full-Service Human Absorption, Metabolism, and Excretion (hAME) Studies with Radiolabeled Compounds at its Clinical Site in Secaucus, NJ.
• Frontage Expands Genomics Services Through the Acquisition of Ocean Ridge Biosciences
• Frontage Holdings Announces 2020 Annual Results
• Frontage Announces Organizational Enhancements to Drive Growth and Integration
• Frontage to Provide Full Service Human Radiolabeled Absorption, Metabolism, and Excretion Study Capabilities in Early 2021
• Mr. Nicholas Pimlett joins Frontage Laboratories, as Vice President of Alliance & Program Management.
• Frontage Holdings Announces 2020 Interim Results
• Frontage announces the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc and President of Frontage Greater China.
• Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.
• ANVISA Certification
• Frontage expands synthetic & medicinal chemistry and process research & development services by acquisition of ACME Bioscience
• Frontage Laboratories, Inc establishes a QWBA Center of Excellence (COE) in Exton PA
• Frontage develops a 3 in 1 multiplex PK assay for evaluation of hydroxy-chloroquine, chloroquine and azithromycin in human plasma
• Frontage Announces the Appointment of Michael J. Potchoiba, M.S to Head the QWBA-Center of Excellence in Exton, PA.
• Frontage Laboratories, Inc. Response to COVID-19 (May 2020)
• Frontage Appoints Dr. Chengwei Fang as Vice President of China Bioanalytical Services
• Frontage Appoints Dr.Xiuxiu Cheng as Chief Scientific Officer of China CMC
• Frontage Expands Drug Metabolism & Pharmacokinetic (DMPK) Services by Acquiring Biotranex
• Frontage Holdings Announces 2019 Annual Results
• Frontage China will add about 215,000 Square Feet of Lab to Expand DMPK and Preclinical Toxicology Services
• Frontage Laboratories, Inc. Response to COVID-19 (March 2020)
• Frontage Welcomes Glenn Washer, BSc, DABT as Executive Vice President, Global Safety & Toxicology Services
• Frontage Completes Expansion of Bioanalytical Capacity and Capabilities
• Frontage Holdings Corporation Selected into Hang Seng Hong Kong-Listed Biotech Index
• Frontage Expanding Geographic Foothold into Canada and the West Coast of North America by Acquisition of BRI
• Promotions of Dr. John Lin, Dr. Abdul Mutlib, Dr. Dongmei Wang
• Frontage Clinical Services Inc. Successfully Implements the ClinSpark® eSource Platform at its Phase I Clinic
• Frontage Expands DMPK Capabilities by Acquisition of RMI
• Frontage Holdings expands CMC service in China by raising its shareholding in Frontage Suzhou to 75%
• Frontage Expands Bioanalytical Capacity and Capabilities to Support Biologic Drug Development, Biomarkers and Cell and Gene Therapy
• Frontage Holdings launched a new 42,000 sq.ft. lab in Shanghai, China
• Frontage Holdings Announces 2019 Interim Results
• Frontage Clinical Services, Inc. Expands Facilities to Accommodate Tobacco and Nicotine-Related Studies
• Frontage Receives 2019 CRO Leadership Awards
• Frontage Holdings Corporation Celebrates a Successful Initial Public Offering on the HKEx
• Frontage Appoints Sridhar Krishnan as Senior Vice President of Global Operations!
• Frontage Appoints Joe (Yifeng) Gao as Chief Financial Officer (CFO)
• Frontage Sponsors the CABS workshop "Preclinical and Early Phase Development of Biologics and Small Molecules"
• Frontage Receives 2018 CRO Leadership Awards
• Dr. Song Li Awarded Entrepreneur Of The Year®
• Dr. Song Li Wins Healthcare CEO Enterprise Award
• Frontage Appoints Hugh Davis as Chief Business Officer
• Frontage acquires Concord Biosciences
• Frontage announces expansion into Princeton, NJ
• Frontage is pleased to announce the appointment of Dr. Luca C. Matassa to the position of Vice President, Bioanalytical Operations & Client Services
• Frontage announces that Dr. Philip Doren has joined Frontage as the President of Clinical Services
• Frontage's sister company, MacroStat, also a Tigermed Company, wins the 2016 Lilly Global Supplier Award
• Frontage becomes the first CRO to complete GLP validation on Simoa HD-1 Analyzer for Biomarker Analysis
• Frontage's affiliate, Frontida, acquires Sun Pharma's Philly and Aurora facilities
• Frontage Bioanalytical Labs go Paperless
• Meet our newest members of the Clinical team
• Frontage Expands Service Offerings to Agrochemical Companies
• Frontage Doubles Bioanalytical Lab Capacity
• Frontage Appoints Dr. Michael S. Willett as President of Clinical Services
• Frontage Expands Clinical Operations in Secaucus, NJ
• Frontage Laboratories Awarded GROW New Jersey Grant for Clinical Operations Expansion
• Frontage Laboratories Recognized as “Fastest Growing Company” by INC Magazine
• Tigermed and Frontage Laboratories Complete Strategic Investment Agreement

Events

• 13th OCT UK & Ireland
• Chinese American Society for Mass Spectrometry
• Neuroscience of Vitality and Aging Conference
• Association for Research in Vision and Ophthalmology
• Drug Discovery Chemistry
• DCAT
• Innovative Biopharmaceutical Association
• EBF
• ACT 47th Annual Meeting
• OCT NE
• AAPS PharmSci 360
• International Society for the Study of Xenobiotics
• SABPA
• LifeSciences Future
• International Conference on Environmental Mutagens
• Contract Pharma
• 17th Annual Bioprocessing Summit
• AAPS Summer Scientific Forum
• Bio International Convention
• CPHI NA
• 39th ACS National Medicinal Chemistry Symposium
• 44th Annual J.P. Morgan Healthcare Conference
• 17th Annual OCT East Coast
• AAPS National Biotechnology Conference
• Delaware's DNA 2026 Life Science Conference
• Swiss Biotech Day
• AACR
• 20th Workshops on Recent Issues in Bioanalysis
• Life Sciences Future Southwest
• Society of Toxicology
• SAPA-GP Annual Conference
• OCT West Coast
• Applied Pharmaceutical Analysis Conference
• Life Science Future
• Blumberg Seminar: From Lead Compound to IND
• Advanced Therapies Congress
• Midwest Regional Chapter Society of Quality Assurance
• Society of Toxicologic Pathology 44th Annual Meeting
• Bio International Convention
• SAPA-NE 27th Annual Conference
• Frontage-Quanterix Joint Webinar
• American College of Toxicology 46th Annual Meeting
• Environmental Mutagenesis and Genomics Society
• Reid Bioanalysis Forum
• Frontage B240 Grand Opening
• Contracting and Outsourcing 24th Annual Conference
• International Society for the Study of Xenobiotics
• KoNECT Conference
• Immunogenicity & Bioassay Summit
• International Congress of Toxicology
• European Bioanalysis Forum 18th Open Symposium
• PharmSci 360
• Outsourcing in Clinical Trials New England
• Discovery on Target 23rd Annual Event
• 17th Annual Bioprocessing Summit
• Alzheimer's Association International Conference
• Society for Birth Defects & Research Prevention Meeting
• SAPA-GP Cell & Gene Therapies 27th Annual Conference
• OCT East Coast
• CPHI Americas
• AACR
• Drug Discovery Chemistry
• WRIB
• DCAT
• Society of Toxicology
• SAPA-GP Annual Conference
• OCT West Coast
• CBA-GP

Resources

• Comparison of Historical Control Ranges in Mouse and Rat -In Vivo Micronucleus Assays Using Flow Cytometric Analysis
• Challenges and Bioanalytical Solutions of Ultra-Low Sensitive 4-in-1 Hormone Biomarkers Method in Human Serum
• Utilization of High Sensitivity Proteomics NULISA HT Panels for Clinical Biomarker Profiling: Assay Qualification and Regulatory Consideration
• In-Vitro Hemolytic Potential of Cyclodextrins: A Species Comparison
• Effect of Theophylline on Respiratory and CNS Parameters in Sprague Daley Rats
• DNA Damage Evaluation of Benzo[b]fluoranthene (B[b]F) Using Rat Liver Comet Assay
• Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden–High Ovarian Cancer
• Population pharmacokinetics of caspofungin in critically ill Chinese children: a prospective observational study
• EBF 2025: A generic immunogenicity assay for the detection of anti-drug antibodies (ADA)in mouse serum samples
• ACT 2025 Study Design Considerations for Wound Healing Research in Göttingen Minipigs
• AAPS 2025: Establishing Linear Viscoelastic Region and Gelation Dynamics in Anhydrous Intra Nasal Gel: Rheological Insights Toward Optimized Patient-Centric Formulations
• AAPS 2025 ENHANCING BIOANALYTICAL LAB EFFICIENCY AND COMPLIANCE THROUGH AN INTEGRATED LAB EXECUTION SYSTEM (LES)
• Duplex Sequencing: A Powerful Tool for In Vivo Gene Mutation
• Genotoxic Potential of Benzo[b]Fluoranthene (B[b]F):A Probable Human Carcinogen
• ACS 2025: Quantitative Analysis of Cyclic Peptide by LC MS/MS with Mixed Acid Modifier Mobile Phases
• AAIC 2025: Comparison of Plasma pTau217 Assays on Different Platforms
• GTA 2025: A375 Human Melanoma Cell Line: Application in Genotoxicity Assessment
• WRIB 2025: Validation of an Ultra-High Sensitive Simoa Assay for the Quantitation of IL-17A in Human Serum
• WRIB 2025: Innovative Strategy for Overcoming pH-Related Assay Variation in the Development and Validation of a Pharmacokinetic Assay for OBI-992, a TROP2-Targeting Exatecan-Based Antibody-Drug Conjugate, in Human Serum
• WRIB 2025: Integrated Non-cell Based and Cell-based NAb Assays for a Complex oHSV Living Drug
• Biomarkers Assay List - July 2025
• STP 2025: Organ Weight Data Interpretation in Toxicology Studies
• BDRP 2025: Comparative Assessment of Dietary Regimens in Rabbit Embryo-Fetal Development Studies
• Drug Metabolism and Pharmacokinetics (DMPK) Services
• WRIB 2024: High-quality RNA-seq Library Preparation from Formalin-Fixed Paraffin-Embedded (FFPE) tissues with GLP and GCLP Compliance
• AAPS 2024: A GxP-Qualified dPCR-Based RCL Assay to Quantify Replication Competent Lentivirus in Bioanalytical Samples
• AACR 2024: Analytical validation of a complete system for detection and characterization of genomic aberrations in circulating tumor DNA
• AACR 2023: Evaluation of a 293 gene oncology-focused exome sequencing panel for screening of ovarian cancer patients for BRCA mutations as a rerequisite for manufacturing of an autologous cellular immunotherapy
• WRIB 2022: Optimization and standardization of RNA-seq operation to get high-quality sequencing data with heavily degraded RNA samples from tumor biopsies
• RNA-Seq Workflow Optimization for Heavily Degraded FFPE Samples with GLP & GCLP Compliance
• Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
• Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product
• Exhibitor Hosted Session SOT 2025 17 Mar 25
• Overview of Cell-Free Assay Services
• In Vitro Cardiac Safety Evaluation
• Webinar Analytical Challenges for CMC Development of Cell and Gene Therapy Products Webinar
• Addressing the Increasing Needs of Data Integrity by Implementing the ElectronicSystems in a Paperless Bioanalytical Laboratory
• Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using the Simoa HD-X platform
• Nonclinical Vehicle Formulations:HP-β-CD (Hydroxypropyl-Beta-Cyclodextrin) & The Risk of Hemolysis
• Evaluating the feasibility of lyophilization for oral formulation development of monoclonal antibodies (mAbs)​
• A GxP-Qualified dPCR-Based RCL Assay to Quantify Replication Competent Lentivirus in Bioanalytical Samples
• Quantitative Assessment of mRNA Drug Biological Activity by Cell-Based Assays​
• IN Vitro Assessment of the inhibition of Human Organic Anion Transporting Polypeptide 1B1/1B3 by Highly Bound Plasma Proteins Compounds in the Presence of Physiological Concentration of Human Serum Albumin 
• Quantitative Analysis of Oligonucleotide by Ion Paring Reversed-Phase LC-MS.MS
• Identification of the Major Circulating Metabolite of Mymd-1 And Elucidation of the Mechanism of Clearance of MYMD-1 in Humans. Role of Aldehyde Oxidase and CYP2A6
• A Hybrid Trial Approach by Combining 13C8-Lableded & Radiolabeled Brilaroxazine to Assess Absolute Bioavailability & hAME in a Single Clinical Trial
• An Unexpected Major Circulating Metabolite M219 Detected in 14C-labeled Human ADME Study of  Brilaroxazine
• Quantitative Analysis of Antibody Conjugate Payload by LC MS/MS without Immunocapture
• Genotoxic Potential of an Antiviral Pyrimidine Nucleoside Analogue, 5-(2-chloroethyl)-2′-deoxyuridine (CEDU)
• From Preclinical Through Phase 1
• CAR-T Cell Therapy Services
• Companion Diagnostics for Alzheimer's Disease
• Metagenomics Services
• Pharmacogenomics Services
• Gene & Cell Therapy Analytical Services
• Biologics Analytical Testing Services
• Biomarkers in Alzheimer's Disease
• CMC-Product Development & Manufacturing Integrated Solutions
• Hepatitis A Virus Infection In Cynomolgus Monkeys Confounds The Safety Evaluation Of A Drug Candidate
• NDA, 505b(2) and ANDA Product Development Services
• Chemistry Services
• Biology Services
• Pharmacology Services
• In Vitro ADME Services
• RNA Sequencing Services
• Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies
• Validating Digital Droplet PCR (ddPCR) Assay with Zero-Inflated Poisson Model
• Development of Stable Nanoemulsion Formulation as an Ophthalmic Drug Delivery System for Cannabinoids
• Analysis of Semi-and Non-Volatile Leachables via an Enhanced HPLC-UV Method
• Cell-Free DNA NGS Testing
• Challenges of Global Drug Development
• Development and validation of an LC-MS/MS method for the quantification of fascin proteins in human serum
• A Competitive Ligand-binding Assay for the Detection of Neutralizing Antibodies Against XTMAB-16
• Validation of a 384 gene hybridization capture-based pharmacogenomics NGS panel: sensitivity, specificity, accuracy, and reproducibility in calling star alleles for drug metabolism genes
• pTau217 Biomarker Assay
• Optimization and standardization of RNA-seq operation to get high-quality sequencing data with heavily degraded RNA samples from tumor​
• Oncology Services
• Immunoassays for Drug Discovery
• Biologics, Gene and Cell Therapy Services
• Precision Medicine and Companion Diagnostics
• DMPK Virtual Tour
• Genomics Services
• Global Drug Discovery Services Overview
• Testing of Carryover & After MRD Benchtop Stability for Pharmacokinetic Method Validation in Gyrolab Immunoassay Platform
• Clinical Services Overview
• Utilizing Ligand Binding Assays (LBA) and Critical Reagents for Drug Development
• Central Lab Test Menu
• Ligand Binding Assays (LBAs) and Critical Reagents
• Alignment on Laboratory Support for Clinical Trials
• General Practices for Critical Reagents Usage in Bioanalytical Labs
• Frontage Hayward, CA Site Virtual Tour
• High Throughput Sample Analysis Using Gyrolab
• Preclinical Drug Screening Using Gyrolab
• Frontage 760 Site Virtual Tour
• Validation of Ultra-high Sensitive SIMOA Assays for the Quantitation of NF-L and GFAP
• Quantitative Whole-Body Autoradiography (QWBA) and Radiation Dosimetry​
• Bioanalysis of antibody-drug conjugates (ADCs) by LC/MS: challenges and solutions
• Sequencing Assays for Biomarker Discovery and Pharmacodynamics in Oncology Studies eBook
• Gut Reaction: Human Microbiome Analysis Insights
• Sterile Nanoemulsion Product Development: Challenges and Future Prospects
• Fact Sheet: Central Lab Services
• GeneTox: A Pivotal Part of Safety Assessment
• GMP Analytical Testing in Gene Therapy Products
• Safety and Toxicology Services Brochure
• Rapid, accurate and highly customizable assay platforms for pharmacogenomic studies
• Guidelines for Developmental and Reproductive Toxicity (DART) Testing
• Human C14 AME (hAME) Services
• 6 Reasons To Do Exploratory Toxicology for Successful GLP Studies
• DART Fact Sheet
• Biomarker and Alzheimer's disease: role of high sensitivity assays and the applications
• Tissue IHC: from R&D to Clinical Lab Testing
• Transcriptome Analysis in Fixed Tumor Biopsy Samples
• Enroll in a Study
• The Next Generation Central Lab
• Biofluid and Exosome Small RNA Sequencing
• 16S rDNA Amplicon Sequencing of Mock Microbial Community Standards
• Liquid Biopsy: Challenges and benefits of cell-free DNA sequencing
• Assay List - May 2023
• Microbiological Testing Considerations for Pharmaceutical Products
• Precision medicine and companion diagnostics
• Companion Diagnostic Biomarkers: Importance, Trend, and Forecast
• DMPK Services Fact Sheet
• The role of genetic toxicology in drug development
• Meeting public health and regulatory demands for next generation consumer products
• Full Service Radiolabeled Human C14 AME (hAME) Studies
• Bioanalytical Methods for Emerging Therapies
• Genomics: A Customized NGS Sequencing
• Neurofilament Light Chain: Method Validation of Quantitation Using the Quanterix Simoa™ Platform and Potential Applications
• Importance of Safety Pharmacology in IND Filings
• Application of ICP-OES/ICP-MS in Pharmaceutical Analysis
• Shanghai, China Virtual Tour - Chinese
• Shanghai, China Virtual Tour - English
• Empowering immune monitoring with ELISpot assays
• Solving Unique ADC Bioanalytical Challenges
• Best Practices in Managing IND Programs with CROs
• Toxicology Services
• Safety Pharmacology Services
• Genetic Toxicology
• Phase 1 Study of OMN54 - Aneustat
• Phase 1 Clinical Development Program
• Safety and Toxicology Virtual Tour
• Gene Therapy Virus Packaging & Quality Control
• Data Management
• Drug Transporters Services
• IND Enabling Services Brochure
• Data Management Infographic
• Instructions For Self Guided Virtual Tour
• Drug-drug Interaction Study of CYP3A4 Inhibitors with Colchicine Oral Solution
• Relative Bioavailability Study of Colchicine Oral Solution and Probenecid/Colchicine Tablets
• Bioanalytical Developments in Cell and Gene Therapies
• No-observed-adverse-effect level (NOAEL) in IND Programs
• Clinical Virtual Tour
• CMC Virtual Tour
• Bioanalytical Virtual Tour
• The Importance of Biomarker Discovery and Personalized Medicine
• BSEPcyte® and MDR3cyte®: Innovative Solutions for Investigating Drug-Induced Liver Injury
• Human Gut Microbiome-Based Contract Research Applications in Toxicology and Microbiome-Based Drug Discovery
• Metabolites in Safety Testing (MIST): Analytical Strategy
• Surrogate Analyte Approaches in Bioanalysis using LC-MS-MS
• MDR3cyte®
• BSEPcyte®
• Strategies and Solutions for Early Phase Formulation Development and CTM Manufacturing
• Development and Validation of an LC-MS.MS Method for the Simultaneous Quantitation of Fifteen Bile Acids in Human Serum
• Cell and Gene Therapy Trends
• First to File Bioequivalency
• IV Infusion
• Complex Diabetes Study
• Requirements for a Derma-Patch Study
• MIST Application Note
• AMAG Pharmaceuticals, Inc. Studies
• Bioanalytical Drug Tolerance Limit Prediction and Optimization Model Developed Through Machine Learning With TensorFlow
• Sterile Product Development of Poorly Water-Soluble Drugs
• Microbiome Services Fact Sheet
• In Vitro BE Study in ANDA Drug Product Development
• Developing an ELISA for residual host cell proteins (HCPs)
• Common Errors in IND-enabling Toxicology Programs
• Stability Testing
• Before GLP: The Value of Robust Exploratory Toxicology
• Analyzing Biomarkers in Drug Development
• IVRT Insights From Frontage CMC Experts
• Accurate Mass: The best solution for metabolite identification in discovery, development and clinical applications.
• Stability Study for EMLA Cream Using In Vitro Percutaneous Absorption
• Evaluating Emerging Tobacco Products and Their Potential Impact on Public Health
• Accurate determination of drug-to-antibody ratio of interchain cysteine-linked antibody–drug conjugates by LC-HRMS
• Intraperitoneal Dose Administration: Successful Testing Using IP Catheters
• PKI Combo™
• Sustainability Initiatives at Frontage
• An Ultrasensitive LC-APPI-MS/MS Method for Simultaneous Determination of Ciclesonide and Active Metabolite Desisobutyryl-Ciclesonide inHuman Serum and Its Application to a Clinical Study
• Hugh Davis for Contract Pharma
• Antibody Drug Conjugate (ADC)
• Nondetectable or minimal detectable residue levels of N-(n-butyl) thiophosphoric triamide in bovine tissues and milk from a 28-d NBPT dosing study
• The Use of Modified Rat Vascular Access ButtonsTM to Refine Repeat Blood Sample Collection in Miniature Pigs
• Overcoming Stability Issues in the Development of an LC-MS/MS Method for the Quantitation of Azacitidine in Human Plasma
• Simultaneous Determination of Coproporphyrin-I and Coproporphyrin-III in Human Plasms and Human Urine Using LC-MS/MS
• Quantitation of Myostatin/GDF-8 in Human Serum Using ELISA
• Achieving sensitive and specific oligonucleotide quantification by hybrid immunoassay and LC–MS/MS
• Bioanalytical Strategies for PK Analysis of ADC Therapeutics using LCMS & LCHRMS
• Bioanalytical Strategies for PK Analysis of Antibody-Drug Conjugates (ADC) using LC–HRMS & LC–MS/MS
• The Value Of Robust Exploratory Toxicology Testing Prior To Pivotal GLP Studies
• Frontage Holdings Launched A New 42,000 Sq.Ft. Lab In Shanghai, China
• Measuring Biological Activity of Biopharmaceuticals with Cell-Based Assays
• Immunocapture-liquid Chromatography/Mass Spectrometry in Simultaneous Quantification of Total Antibody and ADC for XMT-1522 in Human Plasma
• Characterization of Positional Isomers of Interchain Cysteine Linked Antibody−Drug Conjugates by High-Resolution Mass Spectrometry
• Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry
• Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine
• Tobacco
• Gene Therapy
• Dr. Song Li, Frontage’s Founder, Ringing The Bell Of The Hong Kong Stock Exchange
• CMC Stability Testing As A Quality Control Measure
• Validating The Simoa Technology
• Gene Therapy Podcast with Hugh Davis
• Outsourcing Analytical Testing For Biologics - A CRO’s Perspective
• Gene Therapy
• Bioanalysis of Liposome Drugs by LC-MS/MS
• Key Points For Success In A Clinical Trial
• Incorporation of microsampling techniques in bioanalytical assays: DBS and capillary microsampling
• Frontage Laboratories Company Overview Brochure
• CMC-Product Development Services
• CMC GMP Analytical Testing for New Chemical Entities and Commercial Product Support
• CMC GMP Analytical Testing for Biologics
• CMC - CTM Manufacturing
• Clinical & Biometrics Services
• Bioanalytical Mass Spectrometry Services
• Bioanalytical Services Overview
• Bioanalytical Large Molecule / Biologics Services
• Bioanalytical Biomarkers
• Agrochemical
• ADC PK Profiling Strategies on LC-MS Platforms: Top-down, Bottom-up, and Multiplexing
• Quantitation Of Four Chiral Drug Compounds Simultaneously Using Normal Phase LC MS MS Equipped With An APPI Ion Source
• Incorporation of Microsampling Techniques in Bioanalytical Assays
• Pre-Existing Antibodies within Immunogenicity Testing
• Specific Quantitation of Antisense Oligonucleotides in Plasma Using MSD
• Method Validation of Quantitation IL-17A in Human Serum using the Ultrasensitive Quanterix Simoa™ Platform
• Characterization of Interchain Cysteine Linked Antibody Drug Conjugates in Mouse Plasma by LC/MS
• Host Cell Protein Testing: Perspective of Current and Future Techniques
• Assessing Pre-Existing Antibodies (PEXA) in Biotherapeutic Development
• A Novel LC-MS/MS Assay for Quantifying Dermatan Sulfate as a Cerebrospinal Fluid Biomarker for Mucopolysaccharidosis II Disease
• Clinical Study of Abuse-Deterrent Formulation to Suppress Release of Hydrocodone
• Developing and Demonstrating Bioequivalence of Semi-Solid Dosage Forms
• Partnership
• Determination of Pregabalinin Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry
• Development and Validation of an Ultra Sensitive LC-MS/MS Method for Quantitation of Midazolam in Human Plasma
• Comparison of the Quantitative Measurement of Albumin in Human Plasma Using ELISA and uHPLC-High Resolution Mass Spectrometry
• Determination of Fluticasone Propionate and Fluticasone 17&[beta]-Carboxylic Acid Propionate(Fluticasone Metabolite) in Human Plasma by LC/MS/MS
• Validation of a Low-Volume Plasma LC-MS/MS Method Using a CapillaryMicrosampling (CMS) Technique
• Development of a Neutralizing Antibody Assay to support Clinical Trials
• A Capillary Microsampling (CMS) Technique for Low Volume Bioanalytical Plasma Analysis in Support of a Regulated Study
• Recruiting Women for First-in-Human Trials: Tips for Success

Services & Solutions

• Drug Substance Development & Manufacturing
• Product Development
• Standard for Exchange of Nonclinical Data (SEND)
• Toxicokinetics
• Agrochemical
• Central Lab Clinical Trial Request Intake Form
• Central Lab e-Portal
• Biospecimen Data Services
• Stability Program
• GMP Routine Testing Services
• Cell & Gene Therapy Services
• Biologics Services
• Biologics Cell & Gene Therapy
• Sample Management
• Clinical Sample Processing
• Clinical Trial Logistics Services
• Biorepository Services
• Safety Testing & Specialty Lab Testing
• Histology & Pathology
• Pharmacogenetics
• ctDNA Analysis
• NGS Oncology Panel
• Oncology
• Genomics
• Biomarkers & Precision Medicine
• Assays List Finder
• Commercial Manufacturing
• Human 14C AME Study Services
• Clinical Study Experience
• Clinical Services
• Global Pathology Services
• QWBA Studies
• Radiolabeled Studies
• MIST - Metabolites in Safety Testing
• Pharmacokinetics
• In Vivo Services
• Protein Binding and Blood Cell Partitioning
• Permability and Transporters
• Drug-Drug Interaction
• Kinetics & Metabolic Stability
• Metabolite Profiling and Identification
• In Vitro Services
• FTE Services
• Sample Management
• Immunogenicity
• PK/TK Studies
• Services
• Cell Based Assays
• Automation
• Ligand Binding Assay
• Technology Platforms
• Antibody Drug Conjugates
• Modalities
• Method Development & Validation
• Laboratory Testing Services
• Pharmacology
• Process Chemistry Services & Manufacturing
• Medicinal Chemistry
• Custom Synthesis
• Flow Cytometry
• Physicochemical Properties
• Discovery PK & Toxicology
• Biology
• Protein Binding
• Permeability & Transporters
• CYP Interaction
• Metabolic Stability
• ADME • Tox Screening
• Drug Discovery
• Analytical Small Molecule
• Cell and Gene Therapy Services
• Clinical Trial Material (CTM) Manufacturing
• Microbiological Services
• Specialized Toxicology Services
• Developmental and Reproductive Toxicology (DART) Services
• Central Lab Services
• Human C14 AME (hAME) Study Services
• Safety Pharmacology
• Genetic Toxicology
• Formulation Development
• Analytical Services
• CMC-Product Development & Manufacturing
• Large Molecule Bioanalysis • Biologics & Bioassays
• Small Molecule Bioanalysis • Mass Spectrometry
• Bioanalytical - Small & Large Molecules
• Toxicology
• Safety Assessment & Toxicology
• Metabolite Identification
• Drug Metabolism & Pharmacokinetics (DMPK)
• Chemistry
• Drug Development
• Metagenomics & Microbiome
• Data Management
• Medical Writing
• Statistical Programming
• Biostatistics
• Biometrics
• About the Clinic

Clinical Studies

• Y-4-LC-02 (US) Phase 1 Study
• HNC364 - Phase I Clinical Trial
• New Asian Volunteers Needed
• Researchers are studying a new investigational nasal spray version of semaglutide.
• Surgically Sterile Participants
• New Volunteers!
• Referral Program

Clinical Study Forms

• Standard Questions (overweight)
• Surgically Sterile Women
• Asian Participants
• Standard Questions (Spanish)
• Surgically Sterile
• Healthy Adults with Allergen-Induced Oral Physiological Changes
• Non-childbearing Female Study with 2 Parts
• TLL MAD
• (¹⁴C) Study
• Referral Program
• New Subjects
• Standard Questions

People

• Huan Wang, M.S.
• James Huang, Ph.D.
• Wentao Zhang, Ph.D.
• Suden Rao, Ph.D.
• Richard Fischetti
• Jason Liu, Ph.D.
• Abdul Mutlib, Ph.D.
• John Lin, Ph.D.
• Dongmei Wang, Ph.D.
• Song Li, Ph.D.

Europe

• Pharmacokinetics (PK)​
• Contact Us
• Metabolite Identification
• Radio Chemistry & SLIS Synthesis
• Central Lab Logistics
• Bioanalytical - Small & Large Molecules
• Company Overview

News Types

• Featured
• News
• Press Release

Event Types

• Annual Meeting
• Conference
• Convention
• Panel Discussion
• Symposium
• Webinar

Resource Types

• Application Note
• Assay List
• Brochure
• Case Study
• Clinical
• eBook
• Expert Interview
• Fact sheet
• Infographic
• Journal
• Panel Discussion
• Podcast
• Poster
• Presentation
• Studies
• Video
• Virtual Tour
• Webinar
• White Paper

Categories

• Active Study
• New Volunteer Enrollment